
Jason Gertz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1229770/publications.pdf Version: 2024-02-01



LASON CEPTZ

#	Article	IF	CITATIONS
1	ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Research, 2012, 22, 1813-1831.	5.5	1,708
2	Architecture of the human regulatory network derived from ENCODE data. Nature, 2012, 489, 91-100.	27.8	1,384
3	Dynamic DNA methylation across diverse human cell lines and tissues. Genome Research, 2013, 23, 555-567.	5.5	614
4	Widespread plasticity in CTCF occupancy linked to DNA methylation. Genome Research, 2012, 22, 1680-1688.	5.5	494
5	From single-cell to cell-pool transcriptomes: Stochasticity in gene expression and RNA splicing. Genome Research, 2014, 24, 496-510.	5.5	470
6	MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell, 2017, 31, 270-285.	16.8	406
7	Analysis of combinatorial cis-regulation in synthetic and genomic promoters. Nature, 2009, 457, 215-218.	27.8	287
8	Distinct Properties of Cell-Type-Specific and Shared Transcription Factor Binding Sites. Molecular Cell, 2013, 52, 25-36.	9.7	283
9	MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. Cancer Cell, 2020, 38, 60-78.e12.	16.8	262
10	Analysis of DNA Methylation in a Three-Generation Family Reveals Widespread Genetic Influence on Epigenetic Regulation. PLoS Genetics, 2011, 7, e1002228.	3.5	256
11	CTCF/cohesin-mediated DNA looping is required for protocadherin α promoter choice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 21081-21086.	7.1	218
12	Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions. Hormones and Cancer, 2019, 10, 51-63.	4.9	164
13	GIGGLE: a search engine for large-scale integrated genome analysis. Nature Methods, 2018, 15, 123-126.	19.0	154
14	Effects of sequence variation on differential allelic transcription factor occupancy and gene expression. Genome Research, 2012, 22, 860-869.	5.5	150
15	Post-mortem molecular profiling of three psychiatric disorders. Genome Medicine, 2017, 9, 72.	8.2	147
16	Recurrent read-through fusion transcripts in breast cancer. Breast Cancer Research and Treatment, 2014, 146, 287-297.	2,5	141
17	A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nature Cancer, 2022, 3, 232-250.	13.2	133
18	The Hypersensitive Glucocorticoid Response Specifically Regulates Period 1 and Expression of Circadian Genes. Molecular and Cellular Biology, 2012, 32, 3756-3767.	2.3	122

JASON GERTZ

#	Article	IF	CITATIONS
19	Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Research, 2012, 22, 2153-2162.	5.5	121
20	MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion. Clinical Cancer Research, 2019, 25, 5107-5121.	7.0	117
21	Cooperative Dynamics of AR and ER Activity in Breast Cancer. Molecular Cancer Research, 2016, 14, 1054-1067.	3.4	114
22	lκB kinase ε (IKKε) regulates the balance between type I and type II interferon responses. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21170-21175.	7.1	105
23	Transposase mediated construction of RNA-seq libraries. Genome Research, 2012, 22, 134-141.	5.5	85
24	Early de novo DNA methylation and prolonged demethylation in the muscle lineage. Epigenetics, 2013, 8, 317-332.	2.7	85
25	Multiplex Enhancer Interference Reveals Collaborative Control of Gene Regulation by Estrogen Receptor α-Bound Enhancers. Cell Systems, 2017, 5, 333-344.e5.	6.2	85
26	RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with longâ€ŧerm survival and reveals a role for <i>ANGPTL4</i> . Molecular Oncology, 2016, 10, 1169-1182.	4.6	70
27	Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget, 2017, 8, 8226-8238.	1.8	69
28	Clinical and Genomic Crosstalk between Glucocorticoid Receptor and Estrogen Receptor α In Endometrial Cancer. Cell Reports, 2018, 22, 2995-3005.	6.4	52
29	Environmentâ€specific combinatorial <i>cis</i> â€regulation in synthetic promoters. Molecular Systems Biology, 2009, 5, 244.	7.2	45
30	Lentiviral CRISPR Epigenome Editing of Inflammatory Receptors as a Gene Therapy Strategy for Disc Degeneration. Human Gene Therapy, 2019, 30, 1161-1175.	2.7	44
31	Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation. Genome Medicine, 2016, 8, 74.	8.2	43
32	ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells. Cancer Research, 2020, 80, 1234-1245.	0.9	39
33	CRISPR Epigenome Editing of AKAP150 in DRG Neurons Abolishes Degenerative IVD-Induced Neuronal Activation. Molecular Therapy, 2017, 25, 2014-2027.	8.2	35
34	Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects. Cancer Research, 2021, 81, 539-551.	0.9	35
35	Allele-specific distribution of RNA polymerase II on female X chromosomes. Human Molecular Genetics, 2011, 20, 3964-3973.	2.9	34
36	Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of <i>ESR1</i> -Mutant Breast Cancer. Cancer Research, 2021, 81, 732-746.	0.9	34

JASON GERTZ

#	Article	IF	CITATIONS
37	Discovery, validation, and genetic dissection of transcription factor binding sites by comparative and functional genomics. Genome Research, 2005, 15, 1145-1152.	5.5	31
38	Promoter-distal RNA polymerase II binding discriminates active from inactive CCAAT/ enhancer-binding protein beta binding sites. Genome Research, 2015, 25, 1791-1800.	5.5	30
39	Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Research, 2022, 82, 1321-1339.	0.9	30
40	Epistasis in a quantitative trait captured by a molecular model of transcription factor interactions. Theoretical Population Biology, 2010, 77, 1-5.	1,1	29
41	Mapping genome-wide transcription factor binding sites in frozen tissues. Epigenetics and Chromatin, 2013, 6, 30.	3.9	29
42	ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nature Communications, 2022, 13, 2011.	12.8	29
43	Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	28
44	Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer. Genome Research, 2019, 29, 1429-1441.	5.5	27
45	Research Resource: Enhanced Genome-Wide Occupancy of Estrogen Receptor α by the Cochaperone p23 in Breast Cancer Cells. Molecular Endocrinology, 2012, 26, 194-202.	3.7	19
46	Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4. Gut, 2021, 70, 900-914.	12.1	19
47	Improved survival among colon cancer patients with increased differentially expressed pathways. BMC Medicine, 2015, 13, 75.	5.5	18
48	Genetic demultiplexing of pooled single-cell RNA-sequencing samples in cancer facilitates effective experimental design. GigaScience, 2021, 10, .	6.4	17
49	XPRESSyourself: Enhancing, standardizing, and automating ribosome profiling computational analyses yields improved insight into data. PLoS Computational Biology, 2020, 16, e1007625.	3.2	15
50	A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance. Endocrinology, 2021, 162, .	2.8	13
51	A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer. Nature Communications, 2021, 12, 7139.	12.8	12
52	Synergistic CRISPRa-Regulated Chondrogenic Extracellular Matrix Deposition Without Exogenous Growth Factors. Tissue Engineering - Part A, 2020, 26, 1169-1179.	3.1	11
53	Sufficiency analysis of estrogen responsive enhancers using synthetic activators. Life Science Alliance, 2019, 2, e201900497.	2.8	10
54	Phylogeny based discovery of regulatory elements. BMC Bioinformatics, 2006, 7, 266.	2.6	9

JASON GERTZ

#	Article	IF	CITATIONS
55	FFPEcap-seq: a method for sequencing capped RNAs in formalin-fixed paraffin-embedded samples. Genome Research, 2019, 29, 1826-1835.	5.5	9
56	Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. Cancer Research, 2016, 76, 1916-1925.	0.9	7
57	Dissection of Enhancer Function Using Multiplex CRISPR-based Enhancer Interference in Cell Lines. Journal of Visualized Experiments, 2018, , .	0.3	7
58	Regulatory sharing between estrogen receptor α bound enhancers. Nucleic Acids Research, 2020, 48, 6597-6610.	14.5	7
59	Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions. American Journal of Human Genetics, 2022, 109, 1153-1174.	6.2	6
60	A cis-regulatory logic simulator. BMC Bioinformatics, 2007, 8, 272.	2.6	1
61	GENT-18. DIFFERENTIAL BRD4-BOUND STRETCH/SUPER ENHANCERS DRIVE CRITICAL SEX DIFFERENCES IN GBM PHENOTYPE. Neuro-Oncology, 2016, 18, vi77-vi77.	1.2	0